Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients

NCT00201383 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

161

Enrollment

OTHER

Sponsor class

Conditions

Oral Cavity
Squamous Cell Carcinoma

Interventions

DRUG: cisplatin

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]